Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myeloid Malignancies 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Brentuximab Vedotin 13fludarabine 8Cyclophosphamide 8Rituximab 6ruxolitinib 5fludarabine phosphate 5Melphalan 5Lenalidomide 5ponatinib 4Dexamethasone 4Busulfan 4Bortezomib 4nilotinib 3Whole-Body Irradiation 3Vincristine 3Prednisone 3Mycophenolic Acid 3Imatinib Mesylate 3Doxorubicin 3Bendamustine Hydrochloride 3Alemtuzumab 3vosaroxin 2pomalidomide 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Sirolimus 2Ondansetron 2Leukapheresis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hematologic Diseases × cc-486 × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡